[go: up one dir, main page]

EP0661970A4 - Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine. - Google Patents

Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine.

Info

Publication number
EP0661970A4
EP0661970A4 EP19920925405 EP92925405A EP0661970A4 EP 0661970 A4 EP0661970 A4 EP 0661970A4 EP 19920925405 EP19920925405 EP 19920925405 EP 92925405 A EP92925405 A EP 92925405A EP 0661970 A4 EP0661970 A4 EP 0661970A4
Authority
EP
European Patent Office
Prior art keywords
amlodipine
angina
disorders
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19920925405
Other languages
German (de)
French (fr)
Other versions
EP0661970A1 (en
Inventor
James W Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Priority to EP99123828A priority Critical patent/EP1013275A3/en
Priority to EP05107608A priority patent/EP1614420A3/en
Priority to EP02019389A priority patent/EP1262182A3/en
Publication of EP0661970A4 publication Critical patent/EP0661970A4/en
Publication of EP0661970A1 publication Critical patent/EP0661970A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP92925405A 1991-11-26 1992-11-25 Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine Ceased EP0661970A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99123828A EP1013275A3 (en) 1991-11-26 1992-11-25 Method and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
EP05107608A EP1614420A3 (en) 1992-11-25 1992-11-25 Treatment of hypertension, angina and other disorders using (-) amlodipine
EP02019389A EP1262182A3 (en) 1991-11-26 1992-11-25 Methods and compositions for treating hypertension, angina and other disorders using optically pure(-) amlodipine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79846691A 1991-11-26 1991-11-26
US798466 1991-11-26
PCT/US1992/010145 WO1993010779A1 (en) 1991-11-26 1992-11-25 Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP99123828A Division EP1013275A3 (en) 1991-11-26 1992-11-25 Method and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine

Publications (2)

Publication Number Publication Date
EP0661970A4 true EP0661970A4 (en) 1994-12-16
EP0661970A1 EP0661970A1 (en) 1995-07-12

Family

ID=25173478

Family Applications (3)

Application Number Title Priority Date Filing Date
EP99123828A Withdrawn EP1013275A3 (en) 1991-11-26 1992-11-25 Method and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
EP02019389A Ceased EP1262182A3 (en) 1991-11-26 1992-11-25 Methods and compositions for treating hypertension, angina and other disorders using optically pure(-) amlodipine
EP92925405A Ceased EP0661970A1 (en) 1991-11-26 1992-11-25 Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP99123828A Withdrawn EP1013275A3 (en) 1991-11-26 1992-11-25 Method and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
EP02019389A Ceased EP1262182A3 (en) 1991-11-26 1992-11-25 Methods and compositions for treating hypertension, angina and other disorders using optically pure(-) amlodipine

Country Status (5)

Country Link
EP (3) EP1013275A3 (en)
JP (1) JPH07501547A (en)
AU (2) AU3147593A (en)
CA (1) CA2124445A1 (en)
WO (1) WO1993010779A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
CA2270022A1 (en) * 1998-05-14 1999-11-14 Rodney H. Falk Combination of dofetilide and a calcium channel blocker
US6333342B1 (en) 1998-11-04 2001-12-25 Isotechnika, Inc Methods of pharmacological treatment using S(−) amlodipine
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
GB0020842D0 (en) * 2000-08-23 2000-10-11 Pfizer Ltd Therapeutic compositions
AT5874U1 (en) * 2000-12-29 2003-01-27 Bioorg Bv PHARMACEUTICAL PREPARATIONS CONTAINING AMLODIPINMALEAT
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
CN1152013C (en) * 2001-11-22 2004-06-02 张喜田 Levo-amlodipine salt able to generate hydrate and its hydrate and preparation
JP4319148B2 (en) * 2002-09-11 2009-08-26 ハンリム ファーマシューティカル カンパニー リミテッド S-(-)-amlodipine nicotinate and method for producing the same
RU2239433C1 (en) * 2003-06-09 2004-11-10 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Medicinal formulation eliciting vasodilating, anti-anginal, hypotensive and spasmolytic effect and method for its preparing
WO2005070463A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use
US20060035940A1 (en) * 2004-03-16 2006-02-16 Sepracor Inc. (S)-Amlodipine malate
WO2005097191A2 (en) * 2004-04-04 2005-10-20 Sepracor Inc. COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
WO2005099699A1 (en) * 2004-04-07 2005-10-27 Sepracor Inc. Combination of (s)-amlodipine and a beta-blocker, and methods for reducing hypertension
DE602005007763D1 (en) * 2004-10-20 2008-08-07 Emcure Pharmaceuticals Ltd PROCESS FOR PREPARING AN ENANTIOMER OF AMLODIPIN HIGHLY OPTICAL PURITY
WO2008062435A2 (en) * 2006-08-15 2008-05-29 Alkem Laboratories Ltd. Stabilised dosage forms of amlodipine besylate
KR100828883B1 (en) * 2006-10-27 2008-05-09 씨제이제일제당 (주) Separation Method of S-(-)-Amlodipine from Racemic Amlodipine
GB0906868D0 (en) * 2009-04-21 2009-06-03 Rabin Bennie Amlodipine salt compositions
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
CN110882249B (en) 2019-11-08 2021-04-30 北京吾为尔创科技有限公司 Composition containing levamlodipine besylate hydrate and preparation method thereof
CN113209035B (en) * 2021-05-28 2022-07-08 海南锦瑞制药有限公司 Levamlodipine besylate tablets and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089167A2 (en) * 1982-03-11 1983-09-21 Pfizer Limited Dihydropyridine anti-ischaemic and antihypertensive agents, processes for their production, and pharmaceutical compositions containing them
EP0244944A2 (en) * 1986-04-04 1987-11-11 Pfizer Limited Salts of amlodipine
EP0331315A2 (en) * 1988-02-27 1989-09-06 Pfizer Limited Preparation of R- and S-amlodipine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4833191U (en) * 1971-08-23 1973-04-21
GB1438268A (en) * 1974-03-25 1976-06-03 Nelson Research Dev Co Antidepressant
JPS50160949A (en) * 1974-06-21 1975-12-26
NZ198953A (en) * 1980-11-14 1984-10-19 Lilly Co Eli (-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamine,its salts and pharmaceutical formulations
FR2528046B1 (en) * 1982-06-08 1985-06-21 Delalande Sa OPTICALLY ACTIVE OXAZOLIDINONE-2 N-ARYLATED DERIVATIVES, SPECIFIC AND REVERSIBLE INHIBITORS OF TYPE B MONOAMINE OXYDASE AND PROCESS FOR THEIR PREPARATION
NL8202810A (en) * 1982-07-12 1984-02-01 Duphar Int Res SPASMOLYTIC EFFICACY (+) - SECOVERINE.
IT1203721B (en) * 1983-12-29 1989-02-23 Dompe Farmaceutici Spa OPTICALLY ACTIVE COMPOUNDS WITH ANTITOSSE AND CENTRAL SEDATIVE ACTIVITIES, PROCEDURE FOR PREPARATION AND COMPOSITIONS CONTAINING THEM
DE3928287A1 (en) * 1989-08-26 1991-02-28 Knoll Ag USE OF THE (+) - ENANTIOMER OF ANIPAMIL
AU6758990A (en) * 1989-11-06 1991-05-31 Sepracor, Inc. Analgesic composition containing optically pure s(+) flurbiprofen
CA2069404A1 (en) * 1989-11-21 1991-05-22 Timothy J. Barberich Use of optically pure s(-) atenolol for the treatment of cardiovascular disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089167A2 (en) * 1982-03-11 1983-09-21 Pfizer Limited Dihydropyridine anti-ischaemic and antihypertensive agents, processes for their production, and pharmaceutical compositions containing them
EP0244944A2 (en) * 1986-04-04 1987-11-11 Pfizer Limited Salts of amlodipine
EP0331315A2 (en) * 1988-02-27 1989-09-06 Pfizer Limited Preparation of R- and S-amlodipine

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
E.J.ARIËNS: "Racemic therapeutics - ethical and regulatory aspects", EUR.J.CLIN.PHARMACOL., vol. 41, no. 2, June 1991 (1991-06-01), pages 89 - 93 *
E.J.ARIËNS: "Stereoselectivity in pharmacodynamics and pharmacokinetics", SCHWEIZ.MED.WOCHENSCHR., vol. 120, no. 5, 3 February 1990 (1990-02-03), pages 131 - 134 *
J.E.ARROWSMITH ET AL.: "Long-Acting Dihydropyridine Calcium Antagonists. 1. 2-Alkoxymethyl Deivatives Incorporating Basic Substituents", J.MED.CHEM., vol. 29, no. 9, 1986, pages 1696 - 1702, XP002070765, DOI: doi:10.1021/jm00159a022 *
S GOLDMANN ET AL.: "Determination of the Absolute Configuration of the Active Amlodipine Enantiomer as (-)-S: A Correction", J.MED.CHEM., vol. 35, no. 18, 4 September 1992 (1992-09-04), pages 3341 - 3344, XP000877422, DOI: doi:10.1021/jm00096a005 *
See also references of WO9310779A1 *
W.G.NAYLER ET AL.: "(-)[3H]Amlodipine Binding to Rat Cardiac Membranes", J.CARDIOVASC.PHARMACOL., vol. 17, no. 4, 1991, pages 587 - 592, XP000900097 *

Also Published As

Publication number Publication date
JPH07501547A (en) 1995-02-16
EP1262182A2 (en) 2002-12-04
AU3147593A (en) 1993-06-28
AU2221597A (en) 1997-07-31
WO1993010779A1 (en) 1993-06-10
EP1013275A3 (en) 2001-01-10
EP1013275A2 (en) 2000-06-28
EP1262182A3 (en) 2003-02-26
EP0661970A1 (en) 1995-07-12
CA2124445A1 (en) 1993-06-10

Similar Documents

Publication Publication Date Title
EP0661970A4 (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine.
EP0695123A4 (en) Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
ZA971517B (en) Suture collet.
AU5311296A (en) 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
AU3635197A (en) Flourine-containing 1,4 disubstituted piperidine derivatives
EP0754041A4 (en) Novel substituted tryptamines, phenalkylamines and related compounds
AU4073997A (en) 1,4-heterocyclic metallprotease inhibitors
AU3567195A (en) Neurokinin antagonists
HUP0100640A3 (en) Process for the preparation of 1,4-dihydropyridines
IL122372A0 (en) Substituted piperidine-2,6-diones their preparation and use
EP0661971A4 (en) Methods and compositions for treating hypertension, angina, and other disorders using optically pure s(-) felodipine.
FI974435A7 (en) Process for converting 2,4-dichloropyridines into 2-aryloxy-4-chloropyridines
ATE199901T1 (en) 10,11-DIHYDRO-10-OXO-5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE DERIVATIVES
EP0663822A4 (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine.
AU2002301474A1 (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
ZA971999B (en) Disubstituted glutarimide, method for its preparation and its use.
EP0636611A3 (en) Optically active 1,4-dihydropyridine derivatives and process for preparing the same.
IL115136A0 (en) Dibromodstyrene-glycidyl (meth) acrylate copolymers, flame retarded compositions containing the same and methods for the production thereof
HRP970094A2 (en) 1,4-dihydropyridine compounds
AU6074798A (en) Methods and compositions for treating hypertension, angina and other disorders using optically pure S(-) nitrendipine
DK0853606T3 (en) 1,1-difluoro-1,4-dichlorobutane and process for its preparation
AU3084992A (en) 1,4-dihydropyridines for use in the treatment of dermatosis
ZA9810319B (en) Process for the preparation of acetal derivatives of 1,4-dihydropyridines, novel acetal derivatives and the use of the acetal derivatives for the preparation of other 1,4-dihydropyridines.
GB9102031D0 (en) Dihydropyridine compounds,and process for their preparation
AU4586093A (en) Antihypertensive 1,4-dihydropyridine derivatives and process for their preparation

Legal Events

Date Code Title Description
A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940627

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19950920

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APAD Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOS REFNE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20030523

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE